<DOC>
	<DOCNO>NCT00412893</DOCNO>
	<brief_summary>The purpose study compare efficacy safety isavuconazole versus voriconazole treatment patient invasive aspergillosis .</brief_summary>
	<brief_title>Isavuconazole ( BAL8557 ) Primary Treatment Invasive Aspergillosis</brief_title>
	<detailed_description>Acute invasive fungal infection cause aspergillus , zygomycetes filamentous fungi remain life threatening disease . Early treatment highly effective anti-fungals reduces mortality . This study investigate efficacy safety isavuconazole treatment invasive fungal disease , cause Aspergillus filamentous fungi .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Patients must prove , probable possible invasive fungal disease cause Aspergillus specie filamentous fungi Female patient must nonlactating risk pregnancy Patients invasive fungal infection Aspergillus specie filamentous fungi Evidence hepatic dysfunction Baseline moderate severe renal dysfunction Patients chronic aspergillosis , aspergilloma allergic bronchopulmonary aspergillosis Patients receive 4 day systemic antifungal therapy fluconazole within 7 day prior first administration study medication Patients previously enrol Phase III study isavuconazole Patients body weight &lt; /= 40 kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Phase III</keyword>
	<keyword>Invasive fungal disease</keyword>
	<keyword>Aspergillus specie</keyword>
	<keyword>Filamentous fungi</keyword>
	<keyword>ASP9766</keyword>
	<keyword>BAL8557</keyword>
	<keyword>Isavuconazole</keyword>
</DOC>